Results 241 to 250 of about 215,802 (313)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms

British Journal of Pharmacology, EarlyView.
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl, Jakub Morze, Sabina Wallerer, Georg Hoffmann   +3 more
wiley   +1 more source

GRKs and arrestins: Nomenclature and functions in GPCR‐dependent and ‐independent signalling

British Journal of Pharmacology, EarlyView.
G protein‐coupled receptor (GPCR) kinases (GRKs) and arrestins play a critical role in the regulation of GPCR signalling. Historic names of mammalian GRKs were replaced by systematic ones in the 1990s; however, both kinds of names are currently in use for mammalian arrestins.
Vsevolod V. Gurevich
wiley   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source

FXR1‐Directed Alternative Splicing of MK5 Drives Hepatocellular Carcinoma Progression by Activating GSK3β Signaling

Cancer Science, EarlyView.
The RNA‐binding protein FXR1 promotes hepatocellular carcinoma (HCC) progression by driving alternative splicing of MK5 to generate an oncogenic isoform, MK5‐L, which activates the Wnt/β‐catenin pathway. Targeting FXR1 with an antisense oligonucleotide suppresses tumor growth in vivo, revealing a promising therapeutic strategy for HCC.
Yutong Li, Jin Xiang, Bin Cheng, Chenhao Li, Kai Wang, Ni Tang, Luyi Huang   +6 more
wiley   +1 more source

JI‐CJ002 and Dabrafenib Combination Enhances Antitumor Activity in Melanoma Associated With the Downregulation of B7‐H3

Cancer Science, EarlyView.
Schematic pathway diagram illustrating the effects of JI‐CJ002 and dabrafenib on melanoma progression. The combination of JI‐CJ002 and dabrafenib is associated with reduced B7‐H3 expression and modulation of signaling pathways implicated in melanoma progression, including JAK2/STAT3, PI3K/AKT/mTOR, and Rb/E2F1.
Sang‐Eun Lee, Young Ha Kim, Bo Shin Heo, Chunhoo Cheon, Seong‐Gyu Ko   +4 more
wiley   +1 more source

Discovery of a Novel γ‐Glutamylcyclotransferase Inhibitor Plumbagin by Luminescence‐Based High‐Throughput Screening

Cancer Science, EarlyView.
A cell‐based high‐throughput screening system utilizing the luminescent probe LISA‐103 was developed to monitor γ‐glutamylcyclotransferase (GGCT) activity in cancer cells. Through this assay, plumbagin was identified as a novel GGCT inhibitor that induces cell cycle arrest and suppresses cancer cell growth. ABSTRACT γ‐Glutamylcyclotransferase (GGCT) is
Keiko Taniguchi, Yukie Nohara, Mano Horinaka, Kozue Nose, Masaya Mori, Hiromi Ii, Hiroko Kawakami, Kazuto Yano, Susumu Nakata, Taku Yoshiya, Toshiyuki Sakai   +10 more
wiley   +1 more source

Alpha‐B‐crystallin immunohistochemistry: A sensitive but non‐specific marker for epileptogenic lesions

Brain Pathology, EarlyView.
Ekin Güney, Ilay Caliskan, Tara Saunders, Mercedes Paredes, Calixto‐Hope Lucas, Kanish Mirchia, Rufei Lu, Merryl Terry, Erika Cagampan, Melike Pekmezci, Andrew Bollen, Arie Perry, Cathryn R. Cadwell, Tarık Tihan   +13 more
wiley   +1 more source

Hepatocyte TrkB Acts as a Gatekeeper Against MASH‐Related Liver Fibrosis by Suppressing the TGFβ/CCL2 Axis and Macrophage Infiltration

Cell Proliferation, EarlyView.
Hepatocyte TrkB is identified as a critical gatekeeper against MASH‐related fibrosis. Mechanistically, TrkB inhibits the TGFβ/SMAD3/FOS axis to suppress CCL2 secretion, thereby blocking pathogenic macrophage recruitment and ameliorating liver fibrosis.
Yueying Chen, Jiayi Wei, Shuxuan Li, Kefan Yin, Heming Wang, Yicheng Zhao, Shuqiang Weng, Xizhong Shen, Guangqi Song, Changfeng Zhu, Qunyan Yao, Ling Dong   +11 more
wiley   +1 more source

Targeting Egfr‐Mediated Cell Proliferation and Lipid Metabolism Separation Effectively Accelerate Liver Regeneration

Cell Proliferation, EarlyView.
AREG coordinates cell proliferation and lipid metabolism reprogramming during liver regeneration and targeting lipid metabolism can promote liver regeneration. ABSTRACT Hepatocyte proliferation restores liver mass after partial hepatectomy (PHx), but the metabolic cost of this process remains unclear.
Yuelei Hu, Shifei Song, Ruilin Wang, Ni An, Jinmei Diao, Yuguo Chen, Juan Liu, Guoyue Lv   +7 more
wiley   +1 more source